Mesterolone
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Mesterolone: From Androgen Therapy to Gout
One-Sentence Summary
Mesterolone is an oral androgen, marketed in South Africa as Proviron tablets. The TxGNN model predicts it may be effective for gout (score 98.2%), but no clinical trials and no publications were found to support this. This is a model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Oral androgen therapy (the registered indication text is not in the supplied SAHPRA data) |
| Predicted New Indication | Gout |
| TxGNN Prediction Score | 98.20% |
| Evidence Level | L5 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Mesterolone is an androgen. Its registered indication text was not captured, so a direct link to gout cannot be drawn from the supplied data.
The TxGNN score comes from patterns in a biomedical knowledge graph. It is not evidence of a biological mechanism. The supplied data document no mechanistic link between mesterolone and gout, and no comparison with the original indication could be made.
The high score should be treated as a hypothesis-generating signal only. It needs mechanistic and clinical support before it can guide any decision.
Clinical Trial Evidence
Currently no related clinical trials registered. No ClinicalTrials.gov, ICTRP, SANCTR or PACTR records were retrieved for mesterolone in gout.
Literature Evidence
Currently no related literature available for mesterolone in gout.
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| B/21.7/137 | Proviron | Tablet (oral) | Not stated in supplied data |
Essential Medicines List (EML) status was not included in the supplied data.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
No drug interaction records were found in the queried source. This is not evidence that no interactions exist.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone (L5), with no trials, no relevant literature and no documented mechanism. The safety data are also incomplete.
The other nine top predictions were reviewed. All are L5 and also on Hold:
- Type 1 diabetes: the one retrieved paper is about diagnosing pituitary apoplexy and does not study mesterolone.
- Brain small vessel disease with ocular anomalies: the 19 retrieved papers are background reviews on congenital eye anomalies that matched on disease terms. None evaluates mesterolone.
To proceed, the following is needed:
- The SAHPRA Professional Information (warnings, contraindications and approved indication), which is a blocking gap.
- Mechanism of action data, for example from DrugBank.
- A targeted literature search on mesterolone or androgens in gout, including urate levels and gout flares.
- An assessment of the plausibility of a link between androgens and gout, and of safety in the relevant patient population.
- A route and dose-form compatibility check, which is still pending.
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any clinical use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.